📣 VC round data is live. Check it out!
- Public Comps
- Veracyte
Veracyte Valuation Multiples
Discover revenue and EBITDA valuation multiples for Veracyte and similar public comparables like Insight Lifetech, HeartFlow, Dr. Lal PathLabs, BGI Genomics and more.
Veracyte Overview
About Veracyte
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.
Founded
2006
HQ

Employees
824
Website
Financials (LTM)
EV
$2B
Valuation Multiples
Start free trialVeracyte Financials
Veracyte reported last 12-month revenue of $540M and EBITDA of $146M.
In the same LTM period, Veracyte generated $390M in gross profit, $146M in EBITDA, and $74M in net income.
Revenue (LTM)
Veracyte P&L
In the most recent fiscal year, Veracyte reported revenue of $517M and EBITDA of $143M.
Veracyte is profitable as of last fiscal year, with gross margin of 70%, EBITDA margin of 28%, and net margin of 13%.
Financial data powered by Morningstar, Inc.
Veracyte Stock Performance
Veracyte has current market cap of $3B, and enterprise value of $2B.
Market Cap Evolution
Veracyte's stock price is $32.97.
Veracyte share price increased by 0.2% in the last 30 days, and by 23.9% in the last year.
Veracyte has an EPS (earnings per share) of $0.83.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $3B | 0.0% | 0.2% | -9.9% | 23.9% | $0.83 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialVeracyte Valuation Multiples
Veracyte trades at 4.2x EV/Revenue multiple, and 15.4x EV/EBITDA.
EV / Revenue (LTM)
Veracyte Financial Valuation Multiples
As of May 8, 2026, Veracyte has market cap of $3B and EV of $2B.
Veracyte has a P/E ratio of 35.6x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Veracyte Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Veracyte Margins & Growth Rates
Veracyte grew revenue by 13% and EBITDA by 8% in the last fiscal year.
In the most recent fiscal year, Veracyte reported gross margin of 70%, EBITDA margin of 28%, and net margin of 13%.
Veracyte Margins
Veracyte Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Veracyte Operational KPIs
Veracyte's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.3M for the same period.
Veracyte's Rule of 40 is 39% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Veracyte's Rule of X is 59% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Veracyte Competitors
Veracyte competitors include Insight Lifetech, HeartFlow, Dr. Lal PathLabs, BGI Genomics, 10x Genomics, GRAIL, Genus, Fleury, Vimian Group and Twist Bioscience.
Most Veracyte public comparables operate across Medical Imaging & Diagnostics, Diagnostics & Genomics, BioTech, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 31.0x | — | 139.7x | — | |||
| 13.8x | 12.7x | (73.3x) | (63.8x) | |||
| 10.3x | 9.0x | 32.1x | 31.8x | |||
| 3.8x | 3.8x | 48.1x | 44.7x | |||
| 3.7x | 3.8x | 614.0x | (45.6x) | |||
| 10.1x | 9.4x | (3.9x) | (4.1x) | |||
| 2.6x | 2.6x | 14.7x | 13.3x | |||
| 1.4x | 1.5x | 5.1x | 5.7x | |||
This data is available for Pro users. Sign up to see all Veracyte competitors and their valuation data. Start Free Trial | ||||||
Veracyte Funding History
Before going public, Veracyte raised $28M in total equity funding, across 1 round.
Veracyte Funding Rounds
Veracyte M&A Activity
Veracyte has acquired 4 companies to date.
Last acquisition by Veracyte was on January 8th 2024. Veracyte acquired C2i Genomics for $70M (EV/Revenue multiple of ).
Latest Acquisitions by Veracyte
| Description | C2i Genomics is a precision oncology firm delivering cloud-based whole-genome analysis for cancer diagnostics and research. Its services support pharmaceutical trials and companion diagnostics with tumor-normal sequencing and AI-driven variant interpretation. Oslo-headquartered, it partners with global biopharma to advance personalized therapies. | HalioDx is a Marseille, France-headquartered diagnostics company focused on oncology. The firm develops immune contexture tests including Immunoscore that analyze tumor microenvironment to predict patient response to immunotherapy and guide treatment decisions in colorectal and other cancers. | Decipher Biosciences is a Vancouver-based precision oncology company that develops genomic tests like Decipher Prostate and Decipher Bladder for predicting cancer aggressiveness. It maintains the GRID database containing over 70,000 whole-transcriptome profiles from patient samples. Partnerships with Veracyte and pharmaceutical firms such as Pfizer support biomarker discovery for therapies in prostate, bladder, and breast cancers. The company advances tests through clinical validation in North America and Europe. | Allegro Diagnostics is a Maynard, Massachusetts-headquartered molecular diagnostics company focused on pulmonology. Founded in 2006, it develops biomarker-based tests for lung cancer risk assessment and respiratory diseases using samples from Boston University School of Medicine research. |
| HQ Country | ||||
| HQ City | New York City, NY | Marseille | San Diego, CA | Boston, MA |
| Deal Date | 8 Jan 2024 | 1 Jun 2021 | 3 Feb 2021 | 4 Sep 2014 |
| Valuation | $70M | $318M | $600M | $21M |
| EV/Revenue | ||||
| EV/EBITDA | ||||
This data is available for Pro users. Sign up to see all Veracyte acquisitions and their M&A valuation multiples. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Veracyte
| When was Veracyte founded? | Veracyte was founded in 2006. |
| Where is Veracyte headquartered? | Veracyte is headquartered in United States. |
| How many employees does Veracyte have? | As of today, Veracyte has over 824 employees. |
| Who is the CEO of Veracyte? | Veracyte's CEO is Marc A. Stapley. |
| Is Veracyte publicly listed? | Yes, Veracyte is a public company listed on Nasdaq. |
| What is the stock symbol of Veracyte? | Veracyte trades under VCYT ticker. |
| When did Veracyte go public? | Veracyte went public in 2013. |
| Who are competitors of Veracyte? | Veracyte main competitors include Insight Lifetech, HeartFlow, Dr. Lal PathLabs, BGI Genomics, 10x Genomics, GRAIL, Genus, Fleury, Vimian Group, Twist Bioscience. |
| What is the current market cap of Veracyte? | Veracyte's current market cap is $3B. |
| What is the current revenue of Veracyte? | Veracyte's last 12 months revenue is $540M. |
| What is the current revenue growth of Veracyte? | Veracyte revenue growth (NTM/LTM) is 13%. |
| What is the current EV/Revenue multiple of Veracyte? | Current revenue multiple of Veracyte is 4.2x. |
| Is Veracyte profitable? | Yes, Veracyte is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Veracyte? | Veracyte's last 12 months EBITDA is $146M. |
| What is Veracyte's EBITDA margin? | Veracyte's last 12 months EBITDA margin is 27%. |
| What is the current EV/EBITDA multiple of Veracyte? | Current EBITDA multiple of Veracyte is 15.4x. |
| What is the current FCF of Veracyte? | Veracyte's last 12 months FCF is $146M. |
| What is Veracyte's FCF margin? | Veracyte's last 12 months FCF margin is 27%. |
| What is the current EV/FCF multiple of Veracyte? | Current FCF multiple of Veracyte is 15.5x. |
| How many companies Veracyte has acquired to date? | As of May 2026, Veracyte has acquired 4 companies. |
| What was the largest acquisition by Veracyte? | $600M acquisition of Decipher Biosciences on 3rd February 2021 was the largest M&A Veracyte has done to date. |
| What companies Veracyte acquired? | Veracyte acquired Decipher Biosciences, HalioDx, C2i Genomics, and Allegro Diagnostics. |
| In how many companies Veracyte has invested to date? | Veracyte hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Veracyte
Lists including Veracyte
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

